Orthotopic E0771 tumors undergo CD8 T cell–dependent tumor regression with specific antitumor immunity when treated with doxorubicin combined with IL2 (32), but immune-based tumor regression induced by chemotherapy alone, including MEDIC scheduling of CPA (24, 25), has not been reported for either model. The gene discussed is CD8A; the disease is neoplasm.